Results 1 to 10 of about 2,381,535 (223)

In vitro modeling of isoniazid resistance mechanisms in Mycobacterium tuberculosis H37Rv [PDF]

Frontiers in Microbiology, 2023
IntroductionMycobacterium tuberculosis (MTB), the causative agent of tuberculosis, has been a global threat to human beings for several decades. Treating tuberculosis has become more difficult as the prevalence of drug-resistant tuberculosis has ...
Thanadon Dokrungkoon, Orawan Tulyaprawat, Kamol Suwannakarn, Popchai Ngamskulrungroj   +3 more
doaj   +2 more sources

Acetylation of Isoniazid Is a Novel Mechanism of Isoniazid Resistance in Mycobacterium tuberculosis. [PDF]

Antimicrob Agents Chemother, 2020
Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis . The activated drug hinders cell wall biosynthesis by inhibiting the InhA protein. INH-resistant strains of
Arun KB, Madhavan A, Abraham B, Balaji M, Sivakumar KC, Nisha P, Kumar RA.   +6 more
europepmc   +5 more sources

Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system [PDF]

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2022
While there has been progress in detection of drug resistant tuberculosis globally, WHO estimates only about half of the patients with bacteriologically confirmed tuberculosis were tested for rifampicin resistance over the past two years.
Rebecca E. Colman, Christopher Hagan, Peter Chiles, Marva Seifert, Donald G. Catanzaro, Alexander V. Kukhtin, Ryan Norville, Laura Hauns, Arial Bueno, Rebecca C. Holmberg, Christopher G. Cooney, Timothy C. Rodwell   +11 more
doaj   +2 more sources

Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon [PDF]

The Pan African Medical Journal, 2020
INTRODUCTION: It is unclear what the optimal treatment regimen for previously treated patients with rifampicin-susceptible isoniazid resistant tuberculosis should be. Conflicting evidence exists as to the effectiveness of the WHO standardized category II
Christopher Kuaban, Louise Daniele Ingrid Toukam, Melissa Sander   +2 more
doaj   +2 more sources

Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. [PDF]

PLoS ONE, 2012
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy.
Diana Machado, Isabel Couto, João Perdigão, Liliana Rodrigues, Isabel Portugal, Pedro Baptista, Bruno Veigas, Leonard Amaral, Miguel Viveiros   +8 more
doaj   +3 more sources

A duplex one-step recombinase aided PCR assay for the rapid and sensitive detection of the isoniazid resistance genes katG and inhA in Mycobacterium tuberculosis [PDF]

Frontiers in Microbiology
ObjectivesDrug resistance in tuberculosis seriously affects the eradication of tuberculosis, and isoniazid resistance is the second most commonly observed drug resistance in patients with tuberculosis.
Zhiqiang Han, Zhiqiang Han, Zhiqiang Han, Xichao Ou, Ruiqing Zhang, Xiaona Lv, Xiaona Lv, Xiaona Lv, Yuxin Wang, Yuxin Wang, Yuxin Wang, Hongyi Li, Hongyi Li, Hongyi Li, Xinxin Shen, Xuejun Ma, Yanqing Tie   +16 more
doaj   +2 more sources

Characterization of isoniazid resistance and genetic mutations in isoniazid-resistant and rifampicin-susceptible Mycobacterium tuberculosis in China. [PDF]

Infect Med (Beijing)
Patients with tuberculosis resistant to isoniazid but susceptible to rifampicin (Hr-Rs TB) remain a neglected demographic, despite a high disease burden and poor outcomes of these patients. The aim of this study was to investigate the characteristics of isoniazid-resistance-related mutations in Mycobacterium tuberculosis and resistance rates to drugs ...
Liu D, Zhao B, Zheng Y, Ou X, Wang S, Zhou Y, Song Y, Xia H, Wei Q, Zhao Y.   +9 more
europepmc   +4 more sources

Vancomycin rescues sensitivity to isoniazid in clinical isolates of drug-resistant Mycobacterium tuberculosis [PDF]

Microbiology Spectrum
Tuberculosis (TB) continues to be a major global health challenge, with a particularly high incidence of antibiotic resistance in high-burden countries.
Sukriti Pal, Shalini Birua, K. S. Suhas, Raghu Nandan, Chandrani Thakur, Kushi Anand, Sarika Jain Agrawal, N. Somashekar, Amit Singh, Nagasuma Chandra   +9 more
doaj   +2 more sources

Pyrazinamide resistance in rifampicin discordant tuberculosis.

PLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase, Ravesh Singh, Khine Swe Swe-Han, Koleka Patience Mlisana   +3 more
doaj   +2 more sources

Prevalence and Genetic Profiles of Isoniazid Resistance in Tuberculosis Patients: A Multicountry Analysis of Cross-Sectional Data [PDF]

PLoS Medicine, 2020
Maria Cecilia G Ama, Daniela M Cirillo, Katherine Floyd   +2 more
exaly   +2 more sources